Vigilare Wealth Management’s Adaptive Biotechnologies ADPT Stock Holding History

Vigilare Wealth Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-12,875	Closed	-$361K	–	139
2021 Q4	$361K	Buy	12,875 +3,475	+37%	+$107K	0.21%	119
2021 Q3	$320K	Buy	9,400 +350	+4%	+$12.7K	0.2%	141
2021 Q2	$370K	Buy	9,050 +1,870	+26%	+$72.7K	0.22%	121
2021 Q1	$289K	Buy	+7,180	New	+$389K	0.21%	138
2020 Q1	–	Sell	-7,700	Closed	-$231K	–	116
2019 Q4	$231K	Buy	+7,700	New	+$221K	0.15%	127

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vigilare Wealth Management's ADPT Position: Q1 2022 in Review

Vigilare Wealth Management sold out of Adaptive Biotechnologies (ADPT) in Q1 2022, closing a stake of 12,875 shares — an estimated $361K sold.

Vigilare Wealth Management first reported a position in ADPT in Q4 2019 and held it in 5 quarters. The position peaked at $370K in Q2 2021. 221 funds tracked by Wall St. Rank hold ADPT as of Q1 2022.

Vigilare Wealth Management reported no remaining Adaptive Biotechnologies position as of Q1 2022 after selling out during the quarter.
Vigilare Wealth Management sold 12,875 Adaptive Biotechnologies shares in Q1 2022, an estimated $361K.
Vigilare Wealth Management first reported a position in Adaptive Biotechnologies in Q4 2019 and held it in 5 quarters.
Vigilare Wealth Management's Adaptive Biotechnologies position peaked at $370K in Q2 2021.
221 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2022.

Based on Vigilare Wealth Management's 13F filing for Q1 2022, filed 6 Apr 2022.